Wall Street analysts expect Fluidigm Co. (NASDAQ:FLDM) to announce $30.19 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Fluidigm’s earnings, with estimates ranging from $29.80 million to $30.46 million. Fluidigm posted sales of $26.43 million in the same quarter last year, which suggests a positive year-over-year growth rate of 14.2%. The firm is expected to report its next quarterly earnings report after the market closes on Thursday, August 1st.
On average, analysts expect that Fluidigm will report full year sales of $127.90 million for the current fiscal year, with estimates ranging from $126.90 million to $129.70 million. For the next year, analysts expect that the firm will post sales of $141.80 million, with estimates ranging from $139.10 million to $143.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Fluidigm.
Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.30). Fluidigm had a negative return on equity of 43.75% and a negative net margin of 60.45%. The firm had revenue of $30.10 million for the quarter, compared to analyst estimates of $29.18 million. The company’s revenue was up 19.4% on a year-over-year basis.
FLDM has been the topic of several research reports. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. ValuEngine cut Welbilt from a “hold” rating to a “sell” rating in a research note on Wednesday, June 12th. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Piper Jaffray Companies boosted their price target on shares of Marvell Technology Group from $22.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $14.75.
In other Fluidigm news, insider Levin Easterly Partners Llc sold 186,759 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $12.31, for a total value of $2,299,003.29. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nicolas Barthelemy sold 5,100 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.43, for a total value of $63,393.00. The disclosure for this sale can be found here. Insiders sold 566,356 shares of company stock worth $6,964,366 in the last three months. Insiders own 2.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA lifted its stake in Fluidigm by 3,543.1% in the first quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock valued at $91,000 after buying an additional 6,661 shares during the period. Metropolitan Life Insurance Co NY bought a new stake in shares of Fluidigm in the first quarter worth about $151,000. United Services Automobile Association bought a new stake in shares of Fluidigm in the fourth quarter worth about $102,000. Marshall Wace North America L.P. bought a new stake in shares of Fluidigm in the first quarter worth about $159,000. Finally, Ibex Investors LLC bought a new stake in shares of Fluidigm in the first quarter worth about $175,000. 92.64% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:FLDM traded up $0.19 on Friday, reaching $11.49. 657,692 shares of the company were exchanged, compared to its average volume of 876,819. The company has a current ratio of 3.26, a quick ratio of 2.86 and a debt-to-equity ratio of 0.30. Fluidigm has a 1-year low of $5.50 and a 1-year high of $14.90. The company has a market capitalization of $760.95 million, a price-to-earnings ratio of -14.36 and a beta of 2.15. The stock’s 50-day simple moving average is $12.17.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Further Reading: What Are Treasury Bonds?
Get a free copy of the Zacks research report on Fluidigm (FLDM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.